Enrollment Completed in ACACIA-HCM; Topline Results Expected in 1H 2026 CYTOKINETICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE PDUFA Date for Aficamten in Obstructive HCM Extended by FDA to December 26, 2025 Topline Results from MAPLE-HCM Expected in May ~$1.1 Billion in Cash, Cash Equivalents and Investments as of March 31, 2025 SOUTH SAN FRANCISCO, Calif., May 06, 2025 - Cytokinetics, Incorporated (Nasdaq: CYTK) reported a management update and financial results for the fir ...

Core Insights - The FDA has extended the PDUFA date for aficamten in obstructive HCM to December 26, 2025, allowing more time for the review of a REMS submission [3][2] - Cytokinetics is advancing its specialty cardiology pipeline and expects topline results from MAPLE-HCM in May 2025 and from ACACIA-HCM in the first half of 2026 [2][3] Financial Overview - As of March 31, 2025, the company reported approximately $1.1 billion in cash, cash equivalents, and investments, a decrease from $1.2 billion at the end of 2024 [9] - Total revenues for Q1 2025 were $1.6 million, up from $0.8 million in Q1 2024 [10] - R&D expenses for Q1 2025 were $99.8 million, compared to $81.6 million in Q1 2024, primarily due to advancing clinical trials [11] - G&A expenses for Q1 2025 were $57.4 million, an increase from $45.5 million in Q1 2024, attributed to investments in commercial readiness [12] - The net loss for Q1 2025 was $161.4 million, or $(1.36) per share, compared to a net loss of $135.6 million, or $(1.33) per share, in Q1 2024 [13] Clinical Development Updates - Enrollment in ACACIA-HCM has been completed, with over 500 patients enrolled, and topline results are expected in 1H 2026 [3][5] - The primary endpoint for ACACIA-HCM has been updated to include both KCCQ Clinical Summary Score and peak VO2 change [5] - Ongoing clinical trials include COMET-HF for omecamtiv mecarbil and AMBER-HFpEF for CK-586, with expected completion of enrollment in 2026 [4] Corporate Activities - The company is enhancing its commercial readiness for aficamten, including recruiting sales force and establishing distribution partnerships [5] - Cytokinetics has launched EARTH-HCM, an online public health education tool, and awarded grants to patient advocacy organizations [15] - The company maintains its full-year 2025 financial guidance, projecting GAAP operating expenses between $670 million and $710 million [16][17]

Group 1 - The FDA has extended the PDUFA action date for Cytokinetics Inc's aficamten to December 26 from September 26 due to the need for additional time to review the proposed REMS [1][3] - Cytokinetics submitted the NDA for aficamten without an accompanying REMS, but the FDA later requested a REMS based on the drug's characteristics [2] - The submission of the REMS is considered a Major Amendment to the NDA, resulting in a standard three-month extension [3] Group 2 - Cytokinetics' CEO expressed confidence in the benefit-risk profile of aficamten and anticipates a differentiated label upon potential FDA approval [4] - Bristol Myers Squibb's Camzyos did not meet its primary endpoints in a recent Phase 3 trial, which may create an opportunity for aficamten [5] - Analysts believe Cytokinetics is well-positioned to benefit from Bristol Myers' groundwork, with expectations for aficamten to secure a differentiated REMS [6]

U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Friday.Shares of Block, Inc. XYZ fell sharply in today's pre-market trading after the company reported worse-than-expected first-quarter financial results.Block reported quarterly earnings of 56 cents per share, which missed market estimates of 87 cents per share. Quarterly revenue came in at $5.77 billion, missing the consensus estimate of $6.2 billion.Block shares dipped 21.9% to $45.66 in the pre-market trading ...

Core Viewpoint - The FDA has extended the PDUFA action date for Cytokinetics' aficamten to December 26, 2025, due to the need for additional time to review the proposed REMS [1][2]. Group 1: FDA Review Process - Cytokinetics submitted the NDA for aficamten without an accompanying REMS, which was later requested by the FDA during the review process [2]. - The submission of the REMS is considered a Major Amendment to the NDA, resulting in a standard three-month extension to the original PDUFA action date [2]. Group 2: Company Confidence and Product Pipeline - The company remains confident in the benefit-risk profile of aficamten and anticipates a differentiated label and risk mitigation profile upon potential FDA approval [3]. - Cytokinetics is advancing a pipeline of potential new medicines for cardiac muscle dysfunction, including aficamten, omecamtiv mecarbil, CK-586, and CK-089 [3].

Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology, focusing on developing new medicines for cardiac muscle dysfunction [2] - The company is preparing for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, following positive results from the SEQUOIA-HCM Phase 3 clinical trial for obstructive hypertrophic cardiomyopathy (HCM) [2] - Cytokinetics is also developing omecamtiv mecarbil for heart failure with severely reduced ejection fraction (HFrEF), CK-586 for heart failure with preserved ejection fraction (HFpEF), and CK-089 for specific muscular dystrophies and impaired skeletal muscle function [2] Upcoming Events - The management team will participate in a fireside chat at The Citizens Life Sciences Conference on May 7, 2025, at 10:00 AM Eastern Time in New York [5] - The management team will also participate in the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025, at 8:30 AM Eastern Time in New York [5] Investor Access - Interested parties can access live webcasts of the fireside chats through the Investors & Media section of the Cytokinetics website, with replays archived for 90 days post-event [1]

Company Overview - Cytokinetics is a specialty biopharmaceutical company with over 25 years of scientific innovation focused on creating a muscle biology franchise business aimed at optimizing muscle performance for patients with cardiac and other muscle dysfunction diseases [3] Upcoming Financial Results - Cytokinetics is scheduled to report its first quarter results on May 6, 2025, at 4:00 PM Eastern Time, followed by a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates [1] Conference Call Details - The conference call will be available via webcast on Cytokinetics' website, and participants can also join by telephone after registering in advance [2] Product Development - Cytokinetics is preparing for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, following positive results from the SEQUOIA-HCM Phase 3 clinical trial for obstructive hypertrophic cardiomyopathy (HCM) [3] - The company is also developing omecamtiv mecarbil for heart failure with severely reduced ejection fraction (HFrEF), CK-586 for heart failure with preserved ejection fraction (HFpEF), and CK-089 for specific muscular dystrophy and other conditions [3]